Defendant Name: SCWorx Corp.

Defendant Type: Public Company

Document Reference: court_doc4_22-cv-03287

Document Details

Legal Case Name SEC v. Marc S. Schessel and SCWorx Corp.
Document Name Final Judgment as to Defendant SCWorx Corp.
Document Date 02-Jun-2022
Document Format Civil Proceeding
Case Number 22-cv-03287
Federal District Court New Jersey, District of New Jersey
Allegation Type Securities Offering
Document Summary On June 2, 2022, the Court issued a final judgment as to Defendant SCWorx Corp., stating: "Defendant SCWorx Corp. . . . consented to entry of this Final Judgment without admitting or denying the allegations of the Complaint (except as to jurisdiction); waived findings of fact and conclusions of law; and waived any right to appeal from this Final Judgment."

Disgorgement & Penalty Information

Resolutions
Enjoinment
The Court ordered that: "The payment of disgorgement and prejudgment interest shall be deemed satisfied by the transfer by Defendant, no later than 30 days after the entry of the Class Distribution Order in the class action Yannes v. SCWorx Corp., et al., 1:20-cv-03349 (S.D.N.Y.), of shares of SCWorx’s common stock, valued at $600,000 at the time of issuance to authorized claimants in the settlement, provided that the Class Distribution Order is entered within 365 days from the entry of this Final Judgment."
Monetary Penalties:

Disgorgement

Individual:     $471,000.00 Shared:    

Civil Penalty

Individual:     $125,000.00 Shared:    

Pre-Judgment Interest

Individual:     $32,761.56 Shared:    

Related Documents:

comp-pr2022-94 31-May-2022 Complaint
Complaint
The Commission stated: "[i]n April 2020, during the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, NASDAQ-listed securities issuer SCWorx Corp. (ticker: WORX) and its Chief Executive Officer, Schessel, issued false and misleading press releases and other statements claiming that SCWorx would supply millions of COVID-19 test kits to an online healthcare company based in Fairfield, New Jersey ("Telehealth Company"), in exchange for hundreds of millions of dollars. In reality, not only was there no agreement for SCWorx to provide COVID-19 test kits to Telehealth Company, SCWorx did not even have a legitimate supplier for the COVID-19 test kits."
2022-94 31-May-2022 Press Release--Civil Action
SEC Charges Company and Former CEO with Misleading Investors about Sale of COVID-19 Test Kits
The Securities and Exchange Commission "charged New York-based SCWorx Corp. and its former Chief Executive Officer and Chairman of the Board, Marc S. Schessel, with making false and misleading statements about SCWorx's plans to distribute COVID-19 rapid test kits in April 2020. SCWorx has agreed to settle the SEC's charges and will pay a $125,000 civil penalty."

Other Defendants in Action: